Dr. Aaron Cleveland Denson, MD

Dr. Denson practices at Comprehensive Hematology Oncology in Trinity, Florida.

Dr. Denson's NPI, 1861735888, was assigned on March 27, 2013. Dr. Denson graduated from Tulane School of Medicine in 2013. Dr. Denson holds Florida license ME126695.

Dr. Denson's primary practice is Comprehensive Hematology Oncology, at 3611 Little Rd, Trinity, FL 34655 in Pasco County. The practice phone is (727) 344-6570.

Dr. Denson's primary practice is Comprehensive Hematology Oncology in Trinity, Florida. Dr. Denson is also affiliated with HCA Florida Oak Hill Hospital. The medical group on file is Access 2 Health Care Physicians. Dmand AI also links Dr. Denson to 1 more hospital, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Denson practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Denson's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Denson is board certified in hematology by the American Board of Internal Medicine. Dr. Denson is licensed in Florida.

Dmand AI lists breast cancer, chronic anemia, chronic leukemia, colorectal cancer, deep vein thrombosis (DVT), immune deficiency disease, lung cancer and lymphoma among the conditions Dr. Denson treats.

CMS data shows 72,463 Medicare services from Dr. Denson across 51 procedure codes in 2024, for 418 Medicare patients. Medicare paid $856,356 for them. Every service was in an office.

CMS counts 418 Medicare patients who saw Dr. Denson in 2024. The largest group is 75 to 84, with 169 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 8% are also on Medicaid. Their average risk score is 2.12, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Denson's median patient age at 74, with 57% women.

In 2024, Dr. Denson wrote 2,450 Medicare Part D claims for 489 patients. 77% of them were for generic drugs. CMS names the drug for 2,159 of them, across 50 drugs with 11 or more claims each, at $5,443,291 in total drug cost. In 2023, CMS named 2,167 claims across 40 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Denson for performance year 2024, reported individually. Dr. Denson accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 8 papers to Dr. Denson, published from 2015 to 2019. 2019 was the busiest year, with 2. Dr. Denson has published most often in Cancer Control. Dr. Denson's most frequent co-authors are Hyo Sook Han, MD, Hatem H. Soliman, MD and Jonathan R. Strosberg, MD.

CMS Open Payments shows 1,514 general payments to Dr. Denson from 89 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 59% of the total. Novartis Pharmaceuticals Corporation paid the most, $5,070.

Dr. Denson graduated from Tulane School of Medicine in 2013.

Dr. Denson is in network with 19 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 13. Check the plan with the practice before a visit.